{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:37:30Z","timestamp":1794245850319,"version":"4.9.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["6618-21"],"award-info":[{"award-number":["6618-21"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["CRI4838"],"award-info":[{"award-number":["CRI4838"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG2018 ID 21808"],"award-info":[{"award-number":["IG2018 ID 21808"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-65312-y","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:59:30Z","timestamp":1763992770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"given":"Laura Lucia","family":"Cogrossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Policastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Zordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9930-042X","authenticated-orcid":false,"given":"Matteo","family":"Grioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Mattorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3040-0633","authenticated-orcid":false,"given":"Marco","family":"Lorenzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Meregalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Sisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4046-8420","authenticated-orcid":false,"given":"Francesca","family":"Sanvito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-1663","authenticated-orcid":false,"given":"Alessandro","family":"Palmioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-6262","authenticated-orcid":false,"given":"Cristina","family":"Airoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-4637","authenticated-orcid":false,"given":"Aurora","family":"Maurizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4024-8225","authenticated-orcid":false,"given":"Marta","family":"Chesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1822-9861","authenticated-orcid":false,"given":"Nicola","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-8386","authenticated-orcid":false,"given":"Antonio","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-2569","authenticated-orcid":false,"given":"Matteo","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"65312_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard, F. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 10, 45 (2024).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"65312_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00719-0","volume":"12","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar, S. V., Kumar, S., Lonial, S. & Mateos, M. V. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 12, 129 (2022).","journal-title":"Blood Cancer J."},{"key":"65312_CR3","doi-asserted-by":"publisher","first-page":"845422","DOI":"10.3389\/fimmu.2022.845422","volume":"13","author":"A Brevi","year":"2022","unstructured":"Brevi, A., Cogrossi, L. L., Lorenzoni, M., Mattorre, B. & Bellone, M. The insider: Impact of the gut microbiota on cancer immunity and response to therapies in multiple Myeloma. Front Immunol. 13, 845422 (2022).","journal-title":"Front Immunol."},{"key":"65312_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","volume":"13","author":"M Chesi","year":"2008","unstructured":"Chesi, M. et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167\u2013180 (2008).","journal-title":"Cancer Cell"},{"key":"65312_CR5","doi-asserted-by":"publisher","first-page":"e1008850","DOI":"10.1080\/2162402X.2015.1008850","volume":"4","author":"A Calcinotto","year":"2015","unstructured":"Calcinotto, A. et al. Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. Oncoimmunology 4, e1008850 (2015).","journal-title":"Oncoimmunology"},{"key":"65312_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07305-8","volume":"9","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto, A. et al. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat. Commun. 9, 4832 (2018).","journal-title":"Nat. Commun."},{"key":"65312_CR7","doi-asserted-by":"publisher","unstructured":"Bellone M., Brevi A. & Huber S. Microbiota-propelled T helper 17 cells in inflammatory diseases and cancer. Microbiol Mol. Biol. Rev. 84, https:\/\/doi.org\/10.1128\/mmbr.00064-19 (2020).","DOI":"10.1128\/mmbr.00064-19"},{"key":"65312_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41571-018-0006-2","volume":"15","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. The gut microbiota influences anticancer immunosurveillance and general health. Nat. Rev. Clin. Oncol. 15, 382\u2013396 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"65312_CR9","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.3389\/fimmu.2018.02204","volume":"9","author":"F Costa","year":"2018","unstructured":"Costa, F., Das, R., Kini Bailur, J., Dhodapkar, K. & Dhodapkar, M. V. Checkpoint inhibition in myeloma: 0pportunities and challenges. Front. Immunol. 9, 2204 (2018).","journal-title":"Front. Immunol."},{"key":"65312_CR10","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","volume":"28","author":"R Termini","year":"2022","unstructured":"Termini, R. et al. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin. Cancer Res. 28, 4771\u20134781 (2022).","journal-title":"Clin. Cancer Res."},{"key":"65312_CR11","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1158\/2326-6066.CIR-19-0148","volume":"7","author":"AM Lesokhin","year":"2019","unstructured":"Lesokhin, A. M., Bal, S. & Badros, A. Z. Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma. Cancer Immunol. Res 7, 1224\u20131229 (2019).","journal-title":"Cancer Immunol. Res"},{"key":"65312_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/2326-6066.CIR-15-0296","volume":"4","author":"M Ishibashi","year":"2016","unstructured":"Ishibashi, M. et al. Myeloma drug resistance induced by binding of myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunol. Res 4, 779\u2013788 (2016).","journal-title":"Cancer Immunol. Res"},{"key":"65312_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","volume":"28","author":"JA McCulloch","year":"2022","unstructured":"McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med 28, 545\u2013556 (2022).","journal-title":"Nat. Med"},{"key":"65312_CR14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200348119","volume":"119","author":"ZI Hu","year":"2022","unstructured":"Hu, Z. I. et al. Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. Proc. Natl Acad. Sci. USA 119, e2200348119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"65312_CR15","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","volume":"7","author":"D Johnson","year":"2019","unstructured":"Johnson, D. et al. IL17A Blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol. Res. 7, 860\u2013865 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"65312_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48091-w","volume":"15","author":"F Maura","year":"2024","unstructured":"Maura, F. et al. The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans. Nat. Commun. 15, 3844 (2024).","journal-title":"Nat. Commun."},{"key":"65312_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.7","volume":"5","author":"S Yousef","year":"2015","unstructured":"Yousef, S. et al. Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer J. 5, e285 (2015).","journal-title":"Blood Cancer J."},{"key":"65312_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","volume":"120","author":"M Chesi","year":"2012","unstructured":"Chesi, M. et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120, 376\u2013385 (2012).","journal-title":"Blood"},{"key":"65312_CR19","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jid.2019.01.006","volume":"139","author":"S Moos","year":"2019","unstructured":"Moos, S., Mohebiany, A. N., Waisman, A. & Kurschus, F. C. Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes. J. Invest Dermatol 139, 1110\u20131117 (2019).","journal-title":"J. Invest Dermatol"},{"key":"65312_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4049\/jimmunol.1500448","volume":"195","author":"Y Imai","year":"2015","unstructured":"Imai, Y. et al. Cutting Edge: PD-1 regulates imiquimod-induced psoriasiform dermatitis through inhibition of IL-17A expression by innate gammadelta-low T cells. J. Immunol. 195, 421\u2013425 (2015).","journal-title":"J. Immunol."},{"key":"65312_CR21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature09447","volume":"467","author":"K Ghoreschi","year":"2010","unstructured":"Ghoreschi, K. et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 467, 967\u2013971 (2010).","journal-title":"Nature"},{"key":"65312_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1046\/j.1440-1711.1998.00709.x","volume":"76","author":"MJ Barnden","year":"1998","unstructured":"Barnden, M. J., Allison, J., Heath, W. R. & Carbone, F. R. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76, 34\u201340 (1998).","journal-title":"Immunol. Cell Biol."},{"key":"65312_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add3955","volume":"8","author":"V Bosteels","year":"2023","unstructured":"Bosteels, V. et al. LXR signaling controls homeostatic dendritic cell maturation. Sci. Immunol. 8, eadd3955 (2023).","journal-title":"Sci. Immunol."},{"key":"65312_CR24","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1136\/gutjnl-2015-309957","volume":"65","author":"F De Filippis","year":"2016","unstructured":"De Filippis, F. et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut 65, 1812\u20131821 (2016).","journal-title":"Gut"},{"key":"65312_CR25","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1158\/1078-0432.CCR-23-0195","volume":"30","author":"A Rodriguez-Garcia","year":"2024","unstructured":"Rodriguez-Garcia, A. et al. Short-chain fatty acid production by gut microbiota 0redicts Treatment Response in Multiple Myeloma. Clin. Cancer Res. 30, 904\u2013917 (2024).","journal-title":"Clin. Cancer Res."},{"key":"65312_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nri.2016.42","volume":"16","author":"MG Rooks","year":"2016","unstructured":"Rooks, M. G. & Garrett, W. S. Gut microbiota, metabolites and host immunity. Nat. Rev. Immunol. 16, 341\u2013352 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"65312_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.chom.2023.03.016","volume":"31","author":"EJ Culp","year":"2023","unstructured":"Culp, E. J. & Goodman, A. L. Cross-feeding in the gut microbiome: Ecology and mechanisms. Cell Host Microbe 31, 485\u2013499 (2023).","journal-title":"Cell Host Microbe"},{"key":"65312_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.58","volume":"1","author":"R Abdugheni","year":"2022","unstructured":"Abdugheni, R. et al. Metabolite profiling of human-originated Lachnospiraceae at the strain level. Imeta 1, e58 (2022).","journal-title":"Imeta"},{"key":"65312_CR29","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1158\/1078-0432.CCR-22-0723","volume":"28","author":"UA Shah","year":"2022","unstructured":"Shah, U. A. et al. Sustained minimal residual disease negativity in multiple myeloma is associated with stool -butyrate and healthier plant-based fiets. Clin. Cancer Res. 28, 5149\u20135155 (2022).","journal-title":"Clin. Cancer Res."},{"key":"65312_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.immuni.2019.06.002","volume":"51","author":"A Bachem","year":"2019","unstructured":"Bachem, A. et al. Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8(+) T cells. Immunity 51, 285\u2013297 (2019).","journal-title":"Immunity"},{"key":"65312_CR31","doi-asserted-by":"publisher","first-page":"e202895","DOI":"10.1001\/jamanetworkopen.2020.2895","volume":"3","author":"M Nomura","year":"2020","unstructured":"Nomura, M. et al. Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors. JAMA Netw. Open 3, e202895 (2020).","journal-title":"JAMA Netw. Open"},{"key":"65312_CR32","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s43018-023-00636-6","volume":"4","author":"KD Miller","year":"2023","unstructured":"Miller, K. D. et al. Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer. Nat. Cancer 4, 1491\u20131507 (2023).","journal-title":"Nat. Cancer"},{"key":"65312_CR33","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s43018-024-00818-w","volume":"5","author":"S Richard","year":"2024","unstructured":"Richard, S. et al. Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial. Nat. Cancer 5, 1459\u20131464 (2024).","journal-title":"Nat. Cancer"},{"key":"65312_CR34","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","volume":"20","author":"RC Simpson","year":"2023","unstructured":"Simpson, R. C., Shanahan, E. R., Scolyer, R. A. & Long, G. V. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 20, 697\u2013715 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"65312_CR35","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat. Med. 29, 2121\u20132132 (2023).","journal-title":"Nat. Med."},{"key":"65312_CR36","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 24, 1804\u20131808 (2018).","journal-title":"Nat. Med."},{"key":"65312_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.chom.2023.03.020","volume":"31","author":"S Porcari","year":"2023","unstructured":"Porcari, S. et al. Key determinants of success in fecal microbiota transplantation: From microbiome to clinic. Cell Host Microbe 31, 712\u2013733 (2023).","journal-title":"Cell Host Microbe"},{"key":"65312_CR38","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.cell.2023.03.011","volume":"186","author":"MJ Bender","year":"2023","unstructured":"Bender, M. J. et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell 186, 1846\u20131862 (2023).","journal-title":"Cell"},{"key":"65312_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41564-020-00831-6","volume":"6","author":"SH Lee","year":"2021","unstructured":"Lee, S. H. et al. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat. Microbiol. 6, 277\u2013288 (2021).","journal-title":"Nat. Microbiol."},{"key":"65312_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0378-4347(00)00066-9","volume":"741","author":"M Arellano","year":"2000","unstructured":"Arellano, M. et al. Routine analysis of short-chain fatty acids for anaerobic bacteria identification using capillary electrophoresis and indirect ultraviolet detection. J. Chromatogr. B Biomed. Sci. Appl. 741, 89\u2013100 (2000).","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"65312_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-020-00854-5","volume":"8","author":"X Jian","year":"2020","unstructured":"Jian, X. et al. Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria. Microbiome 8, 74 (2020).","journal-title":"Microbiome"},{"key":"65312_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cmet.2023.11.019","volume":"36","author":"Y Zhu","year":"2024","unstructured":"Zhu, Y. et al. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma. Cell Metab. 36, 159\u2013175.e158 (2024).","journal-title":"Cell Metab."},{"key":"65312_CR43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cellimm.2008.04.016","volume":"253","author":"B Wang","year":"2008","unstructured":"Wang, B., Morinobu, A., Horiuchi, M., Liu, J. & Kumagai, S. Butyrate inhibits functional differentiation of human monocyte-derived dendritic cells. Cell Immunol. 253, 54\u201358 (2008).","journal-title":"Cell Immunol."},{"key":"65312_CR44","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41375-023-01874-4","volume":"37","author":"UA Shah","year":"2023","unstructured":"Shah, U. A., Parikh, R., Castro, F., Bellone, M. & Lesokhin, A. M. Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders. Leukemia 37, 964\u2013980 (2023).","journal-title":"Leukemia"},{"key":"65312_CR45","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/bloodadvances.2019032276","volume":"3","author":"MJ Pianko","year":"2019","unstructured":"Pianko, M. J. et al. Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Adv. 3, 2040\u20132044 (2019).","journal-title":"Blood Adv."},{"key":"65312_CR46","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","volume":"108","author":"N Giuliani","year":"2006","unstructured":"Giuliani, N., Rizzoli, V. & Roodman, G. D. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 108, 3992\u20133996 (2006).","journal-title":"Blood"},{"key":"65312_CR47","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","volume":"203","author":"K Sato","year":"2006","unstructured":"Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673\u20132682 (2006).","journal-title":"J. Exp. Med."},{"key":"65312_CR48","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.immuni.2018.10.013","volume":"49","author":"AM Tyagi","year":"2018","unstructured":"Tyagi, A. M. et al. The microbial metabolite butyrate stimulates bone formation via T regulatory cell-mediated regulation of WNT10B expression. Immunity 49, 1116\u20131131.e1117 (2018).","journal-title":"Immunity"},{"key":"65312_CR49","doi-asserted-by":"publisher","unstructured":"Liu, C. et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J. Immunother. Cancer 9, https:\/\/doi.org\/10.1136\/jitc-2020-001895 (2021).","DOI":"10.1136\/jitc-2020-001895"},{"key":"65312_CR50","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/s43018-023-00610-2","volume":"4","author":"R Varaljai","year":"2023","unstructured":"Varaljai, R. et al. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat. Cancer 4, 1292\u20131308 (2023).","journal-title":"Nat. Cancer"},{"key":"65312_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16079-x","volume":"11","author":"C Coutzac","year":"2020","unstructured":"Coutzac, C. et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat. Commun. 11, 2168 (2020).","journal-title":"Nat. Commun."},{"key":"65312_CR52","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.3389\/fimmu.2019.02254","volume":"10","author":"R Anderson","year":"2019","unstructured":"Anderson, R., Theron, A. J. & Rapoport, B. L. Immunopathogenesis of immune checkpoint inhibitor-related adverse events: roles of the intestinal microbiome and Th17 cells. Front. Immunol. 10, 2254 (2019).","journal-title":"Front. Immunol."},{"key":"65312_CR53","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMc1703047","volume":"376","author":"K Esfahani","year":"2017","unstructured":"Esfahani, K. & Miller, W. H. Jr. Reversal of autoimmune toxicity and loss of Tumor Response by Interleukin-17 Blockade. N. Engl. J. Med. 376, 1989\u20131991 (2017).","journal-title":"N. Engl. J. Med."},{"key":"65312_CR54","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4049\/jimmunol.2200244","volume":"209","author":"MG Lechner","year":"2022","unstructured":"Lechner, M. G. et al. Inhibition of IL-17A protects against thyroid immune-related adverse events while preserving checkpoint inhibitor antitumor efficacy. J. Immunol. 209, 696\u2013709 (2022).","journal-title":"J. Immunol."},{"key":"65312_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1073\/pnas.1712901115","volume":"115","author":"F Wang","year":"2018","unstructured":"Wang, F., Yin, Q., Chen, L. & Davis, M. M. Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc. Natl. Acad. Sci. USA 115, 157\u2013161 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65312_CR56","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.chom.2019.01.004","volume":"13","author":"FP De Filippis","year":"2019","unstructured":"De Filippis, F. P. et al. D. Distinct genetic and functional traits of human intestinal prevotella copri strains are associated with different habitual diets. Cell Host Microbe 13, 444\u2013453 (2019).","journal-title":"Cell Host Microbe"},{"key":"65312_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41522-021-00248-x","volume":"7","author":"PKVS Prasoodanan","year":"2021","unstructured":"Prasoodanan, P. K. V. S. et al. V. K. Western and non-western gut microbiomes reveal new roles of Prevotella in carbohydrate metabolism and mouth\u2013gut axis. NPJ Biofilms Microbiomes 7, 1\u201317 (2021).","journal-title":"NPJ Biofilms Microbiomes"},{"key":"65312_CR58","doi-asserted-by":"publisher","unstructured":"Jean-Pierre, F. et al. Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system. Elife 12, https:\/\/doi.org\/10.7554\/elife.81604 (2023).","DOI":"10.7554\/elife.81604"},{"key":"65312_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdent.2020.103539","volume":"104","author":"MA Qudeimat","year":"2021","unstructured":"Qudeimat, M. A., Alyahya, A., Karched, M., Behbehani, J. & Salako, N. O. Dental plaque microbiota profiles of children with caries-free and caries-active dentition. J. Dent. 104, 103539 (2021).","journal-title":"J. Dent."},{"key":"65312_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1271-6","volume":"18","author":"C Wen","year":"2017","unstructured":"Wen, C. et al. Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis. Genome Biol. 18, 142 (2017).","journal-title":"Genome Biol."},{"key":"65312_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202200263","volume":"9","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. Bile acid-microbiome interaction promotes gastric carcinogenesis. Adv. Sci. 9, e2200263 (2022).","journal-title":"Adv. Sci."},{"key":"65312_CR62","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.immuni.2019.02.001","volume":"50","author":"D Yang","year":"2019","unstructured":"Yang, D. et al. Dysregulated lung commensal bacteria drive interleukin-17B production to promote pulmonary fibrosis through their outer membrane vesicles. Immunity 50, 692\u2013706 (2019).","journal-title":"Immunity"},{"key":"65312_CR63","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.celrep.2017.07.031","volume":"20","author":"A Mangalam","year":"2017","unstructured":"Mangalam, A. et al. Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease. Cell Rep. 20, 1269\u20131277 (2017).","journal-title":"Cell Rep."},{"key":"65312_CR64","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1126\/science.abc9113","volume":"373","author":"MEE Griffin","year":"2021","unstructured":"Griffin, M. E. E. et al. Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science 373, 1040\u20131046 (2021).","journal-title":"Science"},{"key":"65312_CR65","first-page":"1","volume":"13","author":"C Cao WZ","year":"2022","unstructured":"Cao WZ, C. et al. Clostridium butyricum potentially improves inflammation and immunity through alteration of the microbiota and metabolism of gastric cancer patients after gastrectomy. Front. Immunol. 13, 1\u201314 (2022).","journal-title":"Front. Immunol."},{"key":"65312_CR66","first-page":"1","volume":"13","author":"B Lin","year":"2022","unstructured":"Lin, B. et al. Randomized clinical trial: probiotics alleviated oral-gut microbiota dysbiosis and thyroid hormone withdrawal-related complications in thyroid cancer patients before radioiodine therapy following thyroidectomy. Front. Endocrinol. 13, 1\u201315 (2022).","journal-title":"Front. Endocrinol."},{"key":"65312_CR67","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1074-7613(02)00391-6","volume":"17","author":"S Nakae","year":"2002","unstructured":"Nakae, S. et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17, 375\u2013387 (2002).","journal-title":"Immunity"},{"key":"65312_CR68","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/leu.2014.70","volume":"28","author":"M Affer","year":"2014","unstructured":"Affer, M. et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28, 1725\u20131735 (2014).","journal-title":"Leukemia"},{"key":"65312_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"65312_CR70","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65312-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65312-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65312-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:03:27Z","timestamp":1771851807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65312-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65312"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65312-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"26 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article the affiliation details for Anna Tosi and Antonio Rosato were incorrectly given as \u20183-Immunology and Molecular Oncology Diagnostics, Istituto Oncologico, Veneto Padua, Italy\u2019 but should have been \u20183-Immunology and Molecular Oncology Diagnostics, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy\u2019. The original article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B. is co-owner of the patent EP18209623.0, \u201cStrategies to improve colonization and expression of\n                      Prevotella melaninogenica\n                      in the gut of patients affected by IL-17-mediated diseases\u201d. M.C. reports grants from NCI during the conduct of the study; grants from Pfizer and nonfinancial support from BMS outside the submitted work; in addition, M.C. has a patent for hCRBN transgenic mice licensed to Novartis and a patent for VkMYC cell line licensed to Pfizer. P.L.B. reports personal fees from CellCentric, grants from NCI, Myeloma Solutions Fund and Paula and Rodger Riney Foundation during the conduct of the study; personal fees from Pfizer, AbbVie, Salarius, Oncopeptides, and GlaxoSmithKline outside the submitted work; in addition, P.L.B. has a patent for hCRBN transgenic mice licensed to Novartis and a patent for VkMYC cell line licensed to Pfizer. All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10384"}}